(Genetic Study of Mucopolysaccharidosis in A Sample of Iraqi Children)
DOI:
https://doi.org/10.31351/vol33iss4pp102-114Keywords:
genetic variants, Iraqi children, mucopolysaccharidosis, single nucleotide polymorphism.Abstract
Mucopolysaccharidosis (MPS) is a rare heterogenous progressive genetic disorder, which is a subset of lysosomal storage diseases with a consequence of glycosaminoglycans building-up inside the lysosomes which attributed to enzymes absence or deficiency. This study was aimed to identify mutations that associated with mucopolysaccharidosis of Iraqi children in different Iraqi metabolic centers. While in concerning to the genetic study, the eligible patients who had no genetic analysis and who are not received hematopoietic stem cells transportation were enrolled in this study for molecular confirmation of mucopolysaccharidosis disorders and reporting the existence of any new variants among Iraqi patients. Consequently, the study reports various SNPs are responsible for different MPS types, for instance, there are seven SNPs within IDAU gene of MPS I Iraqi patients, the most frequent one was rs794726877 which accounts for missense c.152G>A. Finally, the study recommends establishment of awareness programs for affected families regarding the genetic conditions, inheritance pattern and potential availability of reproductive options such as In Vitro Fertilization (IVF), educate the population at risk about the risk of genetic disease transmission as a result of inbreed marriage and necessity of availability of prenatal screening and pregnancy termination option in Iraq.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Kobayashi HJJoHG. Recent trends in mucopolysaccharidosis research. Journal of Human Genetics. 2019;64(2):127-37.
Puckett Y, Mallorga-Hernández A, Montaño AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet Journal of Rare Diseases. 2021;16(1):1-10.
Pierzynowska K, Gaffke L, Cyske Z, Węgrzyn G, Buttari B, Profumo E, et al. Oxidative stress in mucopolysaccharidoses: pharmacological implications. 2021;26(18):1-12.
Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses☆. Molecular Genetics and Metabolism. 2017;2017(1):1-14.
Platt FM, Boland B, van der Spoel ACJJoCB. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. journal of biology. 2012;199(5):723-34.
Gaffke L, Pierzynowska K, Podlacha M, Hoinkis D, Rintz E, Brokowska J, et al. Underestimated aspect of mucopolysaccharidosis pathogenesis: global changes in cellular processes revealed by transcriptomic studies. International Journal of Molecular Sciences. 2020;21(4):1-19.
Pierzynowska K, Gaffke L, Cyske Z, Węgrzyn G, Buttari B, Profumo E, et al. Oxidative stress in mucopolysaccharidoses: pharmacological implications. Molecules. 2021;26(18):1-12.
Fecarotta S, Gasperini S, Parenti GJIjop. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy. Italian Journal of Pediatrics. 2018;44(2):135-43.
Concolino D, Deodato F, Parini RJIjop. Enzyme replacement therapy: efficacy and limitations. Italian Journal of Pediatrics 2018;44(2):117-26.
Grada A, Weinbrecht K. Next-generation sequencing: methodology and application. The Journal of investigative dermatology. 2013;133(8):1-4.
Zanetti A, D’Avanzo F, Rigon L, Rampazzo A, Concolino D, Barone R, et al. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study. European Journal of Pediatrics. 2019;178(2019):739-53.
Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Diseases Research. 2020;9(1):1-9.
13. Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, Wesley J, et al. Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells. 2020;9(8):1-26.
Ferrari S, Ponzin D, Ashworth JL, Fahnehjelm KT, Summers CG, Harmatz PR, et al. Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. British Journal of Ophthalmology. 2011;95(5):613-9.
Kuiper G-A, Meijer OL, Langereis EJ, Wijburg FA. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet journal of rare diseases. 2018;13(2):1-13.
Çakar NE, Karaca M. Evaluation of echocardiographic findings of mucopolysaccharidosis cases. European Archives of Medical Research. 2019;35(3):167-9.
Fateen E, Abdallah ZY, Nazim WS, Ibrahim M, Radwan A. Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt. Heliyon. 2021;7(8):1-9.
Chen X, Qiu W, Ye J, Han L, Gu X, Zhang H. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. Journal of human genetics. 2016;61(4):345-9.
Semyachkina A, Voskoboeva E, Zakharova E, Nikolaeva E, Kanivets I, Kolotii A, et al. Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl. BMC Medical Genetics. 2019;20(1):1-8.
Alsafadi D, Ezzat A, Altamimi F, ElBagoury M, Olfat M, Saleh M, et al. Mucopolysaccharidosis Type I Disease Prevalence Among Patients With Idiopathic Short Stature in Saudi Arabia: Protocol for a Multicenter Cross-sectional Study. JMIR Research Protocols. 2021;10(8):1-8.
21. Turkia B, Tebib N, Azzouz H, Abdelmoula MS, Chehida B, Chemli J, et al. Incidence of mucopolysaccharidoses in Tunisia. La Tunisie Medicale. 2009;87(11):782-5.
22. Pramodh MV, Gowri Ramesh DSJ. Consanguinity as a Risk Factor in the Etiology of Inborn Errors of Metabolism-An Observational Study. Annals of the Romanian Society for Cell Biology. 2021;25(6):10661-9.
Colmenares-Bonilla D, Colin-Gonzalez C, Gonzalez-Segoviano A, Garcia EE, Vela-Huerta MM, Lopez-Gomez FG. Diagnosis of Mucopolysaccharidosis based on history and clinical features: Evidence from the Bajio Region of Mexico. Cureus. 2018;10(11):1-12.
D’Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. European journal of pediatrics. 2012;171(2012):911-9.
Zhang C, Hao S, Meng Z, Hui L, Wang Y, Xuan F, et al. Detailed pedigree analyses and prenatal diagnosis for a family with mucopolysaccharidosis type II. BMC Medical Genomics. 2021;14(1):1-6.
Al-Sannaa NA, Al-Abdulwahed HY, Al-Ghamdi MSJIJND. Lysosomal storage disorders (LSDs): the prevalence in the eastern Province of Saudi Arabia. Int J Neurol Dis. 2017;1(2):38-43.
Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Molecular genetics metabolism. 2017;121(3):227-40.
Abdulelah FM, Mohammed MM, Baaker RH. Prevalence rates of mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study. FResearch. 2023;12(395):1-9.
Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, et al. Prevalence and Novel Mutations of Lysosomal Storage Disorders in United Arab Emirates: LSD in UAE. JIMD. 2013;10(2013):1-9.
Al-Sannaa NA, Al-Abdulwahed HY, Al-Ghamdi MSJIJND. Lysosomal storage disorders (LSDs): the prevalence in the eastern Province of Saudi Arabia. Int J Neurol Dis. 2017;1(2):38-43.
Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki‐Szymanska A, et al. IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel α‐L‐iduronidase (IDUA) alleles. Human mutation. 2011;32(6):1-22.
Amr K, Katoury A, Abdel-Hamid M, Bassiouni R, Ibrahim M, Fateen E. Mutational Analysis of the α-L-Iduronidase Gene in Three Egyptian Families: Identification of Three Novel Mutations and Five Novel Polymorphisms. Genetic Testing Molecular Biomarkers. 2009;13(6):761-4.
Vollebregt AA, Hoogeveen‐Westerveld M, Kroos MA, Oussoren E, Plug I, Ruijter GJ, et al. Genotype–phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype. Developmental Medicine Child Neurology. 2017;59(10):1063-70.
Lin H-Y, Chang Y-H, Lee C-L, Tu Y-R, Lo Y-T, Hung P-W, et al. Newborn screening program for mucopolysaccharidosis type II and long-term follow-up of the screen-positive subjects in Taiwan. Journal of Personalized Medicine. 2022;12(7):1-22.
Burton BK, Hickey R, Hitchins L. Newborn screening for mucopolysaccharidosis type II in Illinois: an update. International journal of neonatal screening. 2020;6(3):1-6.
Terzioglu M, Tokatli A, Coskun T, Emre S. Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: Identification of novel mutations in the N‐acetylgalactosamine‐6‐sulfate sulfatase (GALNS) gene. Human Mutation. 2002;20(6):477-8.
Jezela-Stanek A, Różdżyńska-Świątkowska A, Kulpanovich A, Ciara E, Marucha J, Tylki-Szymańska A. Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe. Journal of applied genetics. 2019;60(2019):163-74.
He D, Huang Y, Ou Z, Sheng H, Li S, Zhao X, et al. Molecular genetic assay of mucopolysaccharidosis IVA in South China. Gene. 2013;532(1):46-52.
Al-Sannaa NA, Al-Abdulwahed HY, Al-Majed SI, Bouholaigah IH. The clinical and genetic spectrum of Maroteaux-Lamy syndrome (mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia. Journal of Community Genetics. 2018;9(2017):65-70.
Varoni EM, Lodi G, Del Fabbro M, Sardella A, Carrassi A, Iriti M, et al. Sex-related differences in allelic frequency of the human beta T cell receptor SNP rs1800907: A retrospective analysis from milan metropolitan area. Vaccines. 2021;9(4):1-8.
Downloads
Published
License
Copyright (c) 2024 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
